Bank of New York Mellon Corp increased its stake in shares of VolitionRX Ltd (NYSEMKT:VNRX) by 177.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 30,376 shares of the medical research company’s stock after purchasing an additional 19,414 shares during the quarter. Bank of New York Mellon Corp owned 0.12% of VolitionRX worth $108,000 at the end of the most recent quarter.

COPYRIGHT VIOLATION NOTICE: “Bank of New York Mellon Corp Has $108,000 Stake in VolitionRX Ltd (VNRX)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at

Separately, HC Wainwright set a $10.00 target price on VolitionRX and gave the stock a “buy” rating in a report on Friday, August 11th.

Shares of VolitionRX Ltd (NYSEMKT VNRX) opened at $2.94 on Wednesday. VolitionRX Ltd has a 1-year low of $2.08 and a 1-year high of $5.45.

About VolitionRX

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

Want to see what other hedge funds are holding VNRX? Visit to get the latest 13F filings and insider trades for VolitionRX Ltd (NYSEMKT:VNRX).

Institutional Ownership by Quarter for VolitionRX (NYSEMKT:VNRX)

Receive News & Stock Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related stocks with our FREE daily email newsletter.